Thyrocare Technologies Limited has announced an additional capital infusion of USD 4,75,000 in its Tanzanian subsidiary, marking another step in the company's international expansion strategy. The investment, made on February 24, 2026, was executed through subscription to Compulsorily Convertible Irredeemable Preference Shares (CCPS) and is equivalent to INR 4,32,91,500.00.

Investment Details and Structure

The latest investment brings the company's total commitment to its Tanzanian operations to USD 11,50,020, equivalent to INR 10,01,62,414. This represents a significant portion of the Board-approved investment limit of up to INR 15 crores for the subsidiary.

Subsidiary Performance and Structure

Thyrocare Laboratories (Tanzania) Limited operates in the diagnostic and healthcare services sector, aligning with the parent company's core business activities. The subsidiary is a joint venture between Thyrocare Technologies Limited and the Kastipharm Group, comprising Kastipharm Limited, Mr. Anwar Alnoor Kachra and Mr. Joseph Philemon Mgaya.

Shareholding Pattern

The investment maintains Thyrocare Technologies' existing shareholding structure in the Tanzanian entity. The company continues to hold a majority stake in equity shares while maintaining complete ownership of the preference shares.

Strategic Rationale

The capital infusion is specifically designed to facilitate business operations and meet working capital requirements of the Tanzanian subsidiary. The company has indicated that remaining capital infusion will be made in one or more tranches, depending on Thyrocare Tanzania's business requirements. The transaction has been structured as a related party transaction conducted at arm's length, with the company confirming that promoters and promoter groups have no other interests beyond those stated.

Regulatory Compliance

The investment disclosure was made under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, in accordance with the SEBI Master Circular dated January 30, 2026. Thyrocare Laboratories (Tanzania) Limited was incorporated in the Republic of Tanzania on September 19, 2023, with Registration Number 168657943.

Thyrocare Technologies Limited announced that its Board of Directors has approved significant amendments to its insider trading compliance framework during a meeting held on January 28, 2026.

Board Meeting Details

The company's Board of Directors convened on Wednesday, January 28, 2026, to consider and approve amendments to the Code of Conduct to Regulate, Monitor and Report Trading by Designated Persons and their Immediate Relatives, commonly referred to as the PIT Code.

Code of Conduct Framework

The amended code establishes comprehensive guidelines under SEBI's Prohibition of Insider Trading Regulations, 2015. The 37-page document outlines detailed procedures for preventing misuse of unpublished price sensitive information (UPSI) and establishes trading restrictions for designated persons.

Key components of the amended code include:

• Trading Window Restrictions: Closure from end of every quarter until 48 hours after financial results declaration
• Pre-clearance Requirements: Mandatory approval for all trades by designated persons during open trading windows
• Disclosure Obligations: Initial and continual disclosure requirements for securities transactions exceeding ₹10,00,000
• Structured Digital Database: Maintenance of records for persons with whom UPSI is shared

Compliance and Monitoring Mechanisms

The code designates the Company Secretary as the Compliance Officer, responsible for monitoring adherence to insider trading regulations. The framework includes specific provisions for trading plans, reporting requirements, and penalty structures for violations.

Regulatory Disclosure

The company has fulfilled its disclosure obligations under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations, 2015. The amended PIT Code has been made available on the company's investor website at https://investor.thyrocare.com/policies-codes/ .

This amendment reflects Thyrocare Technologies' commitment to maintaining robust corporate governance standards and ensuring compliance with evolving regulatory requirements in the Indian securities market.